Arcus Biosciences, Inc. (RCUS)
15.62
-0.16
(-1.01%)
USD |
NYSE |
Nov 20, 16:00
15.64
+0.02
(+0.13%)
Pre-Market: 20:00
Arcus Biosciences Shareholders Equity (Quarterly) : 358.00M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 358.00M |
| June 30, 2026 | 464.00M |
| March 31, 2026 | 524.00M |
| December 31, 2025 | 631.00M |
| September 30, 2025 | 436.00M |
| June 30, 2025 | 549.00M |
| March 31, 2025 | 531.00M |
| December 31, 2024 | 485.00M |
| September 30, 2024 | 565.00M |
| June 30, 2024 | 635.00M |
| March 31, 2024 | 707.00M |
| December 31, 2023 | 462.00M |
| September 30, 2023 | 520.00M |
| June 30, 2023 | 566.00M |
| March 31, 2023 | 600.00M |
| December 31, 2022 | 657.00M |
| September 30, 2022 | 698.70M |
| June 30, 2022 | 747.39M |
| Date | Value |
|---|---|
| March 31, 2022 | 796.58M |
| December 31, 2021 | 841.45M |
| September 30, 2021 | 542.61M |
| June 30, 2021 | 604.56M |
| March 31, 2021 | 664.79M |
| December 31, 2020 | 502.30M |
| September 30, 2020 | 544.42M |
| June 30, 2020 | 428.71M |
| March 31, 2020 | 140.64M |
| December 31, 2019 | 163.84M |
| September 30, 2019 | 177.23M |
| June 30, 2019 | 196.65M |
| March 31, 2019 | 221.57M |
| December 31, 2018 | 234.94M |
| September 30, 2018 | 245.12M |
| June 30, 2018 | 254.57M |
| March 31, 2018 | 266.59M |
| December 31, 2017 | 153.87M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Halozyme Therapeutics, Inc. | -55.24M |
| AVITA Medical, Inc. | -31.04M |
| Iovance Biotherapeutics, Inc. | 812.66M |
| Editas Medicine, Inc. | 84.52M |
| Recursion Pharmaceuticals, Inc. | 905.81M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 818.00M |
| Total Liabilities (Quarterly) | 460.00M |
| Debt to Equity Ratio | 0.324 |
| Current Ratio | 3.337 |
| Net Debt Paydown Yield | -0.04% |